Clinical Trial Update: Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan [Phase 3]

View source ↗

Summary

Phase 3 trial assessing reduced-dose efavirenz (400 mg) in a fixed-dose combination for virologic suppression in HIV patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Yu-Jay Corp. | Conditions: HIV Infections | Phase 3 | Status: COMPLETED